

AMP case report: February 2017 test yourself answers

In the February 2017 issue was a report, "[An unusual BRAF mutation in a patient with melanoma](#)," written by members of the Association for Molecular Pathology. Here are answers (in bold) to the three "test yourself " questions that followed that case report.

1. What percentage of melanoma patients have an activating **BRAF** mutation?

- a) 20-40 percent
- b) 40-60 percent**
- c) 60-80 percent
- d) 80-100 percent

2. At present, why isn't next-generation sequencing the first-line test for **BRAF**?

- a) It has a low sensitivity.
- b) It has a low specificity.
- c) It has a longer turnaround time compared with other tests.**

3. Why is it important to test the **BRAF** mutational status in melanoma patients?

- a) Some BRAF inhibitors are specific to V600E.**
- b) **BRAF** mutations can confirm a melanoma diagnosis.
- c) It provides useful information about tumor staging.